Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis.

Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series

(2008) · doi:10.1002/9780470712184 · Cited by 25,048 · see citing works

Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy

Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetes Care · doi:10.2337/dc08-9025 · Cited by 3,834 · see citing works

Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes

DeFronzo, R. A., Ratner, R. E., Han, J., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1092 · Cited by 1,559 · see citing works

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)

Buse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., & Blonde, L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60659-0 · Cited by 1,503 · see citing works

Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.

Flint, A., Raben, A., Astrup, A., & Holst, J. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci990 · Cited by 1,402 · see citing works

Variance imputation for overviews of clinical trials with continuous response

Follmann, D. A., Elliott, P., Suh, I., & Cutler, J. A. (1992) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(92)90054-q · Cited by 1,391 · see citing works

Effects of exenatide (Exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes

Buse, J. B., Henry, R. R., Han, J., Kim, D. D., Fineman, M. S., Baron, A. D., & for the Exenatide-113 Clinical Study Group (2004) · Diabetes Care · doi:10.2337/diacare.27.11.2628 · Cited by 1,346 · see citing works

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea

Kendall, D. M., Riddle, M. C., Rosenstock, J., Zhuang, D., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1083 · Cited by 1,177 · see citing works

Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes

Nauck, M., Frid, A., Hermansen, K., Shah, N. S., Tankova, T., Mitha, I. H., Zdravkovic, M., Düring, M., Matthews, D. R., & for the LEAD-2 Study Group (2009) · Diabetes Care · doi:10.2337/dc08-1355 · Cited by 1,129 · see citing works

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study

Drucker, D. J., Buse, J. B., Taylor, K., Kendall, D. M., Trautmann, M., Zhuang, D., & Porter, L. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61206-4 · Cited by 1,070 · see citing works

Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial

Garber, A., Henry, R., Ratner, R., Garcia-Hernandez, P. A., Rodriguez-Pattzi, H., Olvera-Alvarez, I., Hale, P. M., Zdravkovic, M., & Bode, B. (2009) · The Lancet · doi:10.1016/s0140-6736(08)61246-5 · Cited by 1,057 · see citing works

Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials

Vilsboll, T., Christensen, M., Junker, A. E., Knop, F. K., & Gluud, L. L. (2012) · BMJ · doi:10.1136/bmj.d7771 · Cited by 970 · see citing works

Efficacy and Safety of the Human Glucagon-Like Peptide-1 Analog Liraglutide in Combination With Metformin and Thiazolidinedione in Patients With Type 2 Diabetes (LEAD-4 Met+TZD)

Zinman, B., Gerich, J., Buse, J. B., Lewin, A., Schwartz, S., Raskin, P., Hale, P. M., Zdravkovic, M., Blonde, L., & the LEAD-4 Study Investigators (2009) · Diabetes Care · doi:10.2337/dc08-2124 · Cited by 848 · see citing works

Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial

on behalf of the Liraglutide Effect and Action in Diabetes 5 (LEAD-5) met+SU Study Group, Russell-Jones, D., Vaag, A., Schmitz, O., Sethi, B. K., Lalic, N., Antic, S., Zdravkovic, M., Ravn, G. M., & Simó, R. (2009) · Diabetologia · doi:10.1007/s00125-009-1472-y · Cited by 835 · see citing works

Liraglutide, a once‐daily human GLP‐1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD‐1 SU)

Marre, M., Shaw, J. E., Brändle, M., Bebakar, W. M. W., Kamaruddin, N. A., Strand, J., Zdravkovic, M. D., Thi, T. D. L., Colagiuri, S., & on behalf of the LEAD‐1 SU study group (2009) · Diabetic Medicine · doi:10.1111/j.1464-5491.2009.02666.x · Cited by 814 · see citing works

Exenatide versus Insulin Glargine in Patients with Suboptimally Controlled Type 2 Diabetes: A Randomized Trial

Heine, R. J., Van Gaal, L. F., Johns, D., Mihm, M. J., Widel, M. H., Brodows, R. G., & for the GWAA Study Group* (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-143-8-200510180-00006 · Cited by 795 · see citing works

Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years

Klonoff, D. C., Buse, J. B., Nielsen, L. L., Guan, X., Bowlus, C. L., Holcombe, J. H., Wintle, M. E., & Maggs, D. G. (2008) · Current Medical Research and Opinion · doi:10.1185/030079908x253870 · Cited by 699 · see citing works

Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial

Bergenstal, R. M., Wysham, C., MacConell, L., Malloy, J. L., Walsh, B., Yan, P., Wilhelm, K., Malone, J., & Porter, L. E. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60590-9 · Cited by 607 · see citing works

The Multiple Actions of GLP-1 on the Process of Glucose-Stimulated Insulin Secretion

MacDonald, P. E., El-kholy, W., Riedel, M. J., Salapatek, A. M. F., Light, P. E., & Wheeler, M. B. (2002) · Diabetes · doi:10.2337/diabetes.51.2007.s434 · Cited by 590 · see citing works

Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial

Pratley, R. E., Nauck, M. A., Bailey, T. S., Montanya, E., Cuddihy, R. M., Filetti, S., Thomsen, A. B., Søndergaard, R. E., & Davies, M. J. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60307-8 · Cited by 582 · see citing works

Use of Twice-Daily Exenatide in Basal Insulin–Treated Patients With Type 2 Diabetes: A Randomized, Controlled Trial

Buse, J. B., Bergenstal, R. M., Glass, L. C., Heilmann, C. R., Lewis, M. S., Kwan, A. Y. M., Hoogwerf, B. J., & Rosenstock, J. (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-154-2-201101180-00300 · Cited by 506 · see citing works

Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients.

Willms, B., Werner, J., Holst, J. J., Orskov, C., Creutzfeldt, W., & Nauck, M. A. (1996) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.81.1.8550773 · Cited by 502 · see citing works

Liraglutide, a Long-Acting Human Glucagon-Like Peptide-1 Analog, Given as Monotherapy Significantly Improves Glycemic Control and Lowers Body Weight Without Risk of Hypoglycemia in Patients With Type 2 Diabetes

Vilsbøll, T., Zdravkovic, M., Le-Thi, T., Krarup, T., Schmitz, O., Courrèges, J. P., Verhoeven, R., Bugáňová, I., & Madsbad, S. (2007) · Diabetes Care · doi:10.2337/dc06-2593 · Cited by 467 · see citing works

DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes

Blevins, T., Pullman, J., Malloy, J., Yan, P., Taylor, K., Schulteis, C., Trautmann, M., & Porter, L. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-2081 · Cited by 448 · see citing works

Effects of Once-Weekly Dosing of a Long-Acting Release Formulation of Exenatide on Glucose Control and Body Weight in Subjects With Type 2 Diabetes

Kim, D. S., MacConell, L., Zhuang, D., Kothare, P. A., TRAUTMANN, M. E., Fineman, M. S., & Taylor, K. (2007) · Diabetes Care · doi:10.2337/dc06-2375 · Cited by 447 · see citing works

Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial

Diamant, M., Van Gaal, L., Stranks, S., Northrup, J., Cao, D., Taylor, K., & Trautmann, M. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60406-0 · Cited by 434 · see citing works

A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study

Nauck, M. A., Duran, S., Kim, D., Johns, D., Northrup, J., Festa, A., Brodows, R. G., & TRAUTMANN, M. E. (2006) · Diabetologia · doi:10.1007/s00125-006-0510-2 · Cited by 430 · see citing works

The Effect of Adding Exenatide to a Thiazolidinedione in Suboptimally Controlled Type 2 Diabetes

Zinman, B., Hoogwerf, B. J., García, S. D., Milton, D. R., Giaconia, J. M., Kim, D. D. H., TRAUTMANN, M. E., & Brodows, R. G. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-7-200704030-00003 · Cited by 422 · see citing works

One-Year Treatment With Exenatide Improves β-Cell Function, Compared With Insulin Glargine, in Metformin-Treated Type 2 Diabetic Patients

Bunck, M. C., Diamant, M., Cornér, A., Eliasson, B., Malloy, J. L., Shaginian, R. M., Deng, W., Kendall, D. M., Taskinen, M.-R., Smith, U., et al. (2009) · Diabetes Care · doi:10.2337/dc08-1797 · Cited by 388 · see citing works

DURATION-1: Exenatide Once Weekly Produces Sustained Glycemic Control and Weight Loss Over 52 Weeks

Buse, J. B., Drucker, D. J., Taylor, K., Kim, T., Walsh, B., Hu, H., Wilhelm, K., TRAUTMANN, M. E., Shen, L. Z., Porter, L. E., et al. (2010) · Diabetes Care · doi:10.2337/dc09-1914 · Cited by 357 · see citing works

Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: A randomized, double-blind, placebo-controlled, parallel-group study

Moretto, T. J., Milton, D. R., Ridge, T. D., MacConell, L. A., Okerson, T., Wolka, A. M., & Brodows, R. G. (2008) · Clinical Therapeutics · doi:10.1016/j.clinthera.2008.08.006 · Cited by 350 · see citing works

Efficacy and Safety of Exenatide Once Weekly Versus Metformin, Pioglitazone, and Sitagliptin Used as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4)

Russell-Jones, D. L., Cuddihy, R. M., Hanefeld, M., Kumar, A., González‐González, J. G., Chan, M., Wolka, A. M., Boardman, M. K., & on behalf of the DURATION-4 Study Group (2011) · Diabetes Care · doi:10.2337/dc11-1107 · Cited by 334 · see citing works

Glucagon-like peptide 1(GLP-1) in biology and pathology

Meier, J. J., & Nauck, M. A. (2005) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.538 · Cited by 288 · see citing works

Editorial

(1997) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(97)00246-5 · Cited by 280 · see citing works

Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: An interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials

Buse, J. B., Klonoff, D. C., Nielsen, L. L., Guan, X., Bowlus, C. L., Holcombe, J. H., Maggs, D. G., & Wintle, M. E. (2007) · Clinical Therapeutics · doi:10.1016/j.clinthera.2007.01.015 · Cited by 279 · see citing works

One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial

Pratley, R. E., Nauck, M. A., Bailey, T. S., Montanya, E., Cuddihy, R. M., Filetti, S., Garber, A. J., Thomsen, A. B., Hartvig, H. B., Davies, M. J., et al. (2011) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2011.02656.x · Cited by 253 · see citing works

Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: A multinational, randomized, open-label, two-period, crossover noninferiority trial

Barnett, A. H., Burger, J., Johns, D., Brodows, R. G., Kendall, D. M., Roberts, A., & TRAUTMANN, M. E. (2007) · Clinical Therapeutics · doi:10.1016/j.clinthera.2007.11.006 · Cited by 240 · see citing works

Effects of exenatide on measures of β-cell function after 3 years in metformin-treated patients with type 2 diabetes

Bunck, M. C., Cornér, A., Eliasson, B., Heine, R. J., Shaginian, R. M., Taskinen, M.-R., Smith, U., Yki-Järvinen, H., & Diamant, M. (2011) · Diabetes Care · doi:10.2337/dc11-0291 · Cited by 240 · see citing works

The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1–5 studies

Blonde, L., & Russell-Jones, D. L. (2009) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01075.x · Cited by 227 · see citing works

Long‐term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over‐weight metformin‐treated patients with type 2 diabetes mellitus

Ratner, R. E., Maggs, D., Nielsen, L. L., Stonehouse, A. H., Poon, T., Zhang, B., Bicsak, T. A., Brodows, R. G., & Kim, D. D. (2006) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2006.00589.x · Cited by 217 · see citing works

An overview of once‐weekly glucagon‐like peptide‐1 receptor agonists—available efficacy and safety data and perspectives for the future

Madsbad, S., Kielgast, U. L., Asmar, M., Deacon, C. F., Torekov, S. S., & Holst, J. J. (2011) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01357.x · Cited by 201 · see citing works

Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open-label, randomised controlled trial

Gallwitz, B., Guzman, J., Dotta, F., Guerci, B., Simó, R., Basson, B. R., Festa, A., Kiljanski, J. I., Sapin, H., TRAUTMANN, M. E., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60479-6 · Cited by 158 · see citing works

Meta-analysis of individual patient data in randomised trials of self monitoring of blood glucose in people with non-insulin treated type 2 diabetes

Farmer, A. J., Perera, R., Ward, A., Heneghan, C., Oke, J., Barnett, A. H., Davidson, M. B., Guerci, B., Coates, V., Schwedes, U., et al. (2012) · BMJ · doi:10.1136/bmj.e486 · Cited by 156 · see citing works

Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes

Ratner, R. E., Han, J., Nicewarner, D., Yushmanova, I., Hoogwerf, B. J., & Shen, L. Z. (2011) · Cardiovascular Diabetology · doi:10.1186/1475-2840-10-22 · Cited by 152 · see citing works

Effects of liraglutide (NN2211), a long‐acting GLP‐1 analogue, on glycaemic control and bodyweight in subjects with Type 2 diabetes

Feinglos, M. N., Saad, M. F., Pi-Sunyer, F. X., An, B., Santiago, O. M., & on behalf of the Liraglutide Dose‐Response Study Group (2005) · Diabetic Medicine · doi:10.1111/j.1464-5491.2005.01567.x · Cited by 151 · see citing works

Exenatide compared with long‐acting insulin to achieve glycaemic control with minimal weight gain in patients with type 2 diabetes: results of the Helping Evaluate Exenatide in patients with diabetes compared with Long‐Acting insulin (HEELA) study

Davies, M. J., Donnelly, R., Barnett, A. H., Jones, S., Nicolay, C., & Kilcoyne, A. (2009) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01154.x · Cited by 144 · see citing works

Prognostic Value of Home Heart Rate for Cardiovascular Mortality in the General Population: The Ohasama Study

Hozawa (2004) · American Journal of Hypertension · doi:10.1016/j.amjhyper.2004.06.019 · Cited by 136 · see citing works

Effect of exenatide on heart rate and blood pressure in subjects with type 2 diabetes mellitus: a double-blind, placebo-controlled, randomized pilot study

Gill, A. M., Hoogwerf, B. J., Burger, J., BRUCE, S. R., MacConell, L., Yan, P., Braun, D. K., Giaconia, J. M., & Malone, J. K. (2010) · Cardiovascular Diabetology · doi:10.1186/1475-2840-9-6 · Cited by 134 · see citing works

One-year treatment with exenatide vs. Insulin Glargine: Effects on postprandial glycemia, lipid profiles, and oxidative stress

Bunck, M. C., Cornér, A., Eliasson, B., Heine, R. J., Shaginian, R. M., Wu, Y., Yan, P., Smith, U., Yki-Järvinen, H., Diamant, M., et al. (2010) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2010.04.024 · Cited by 132 · see citing works

Effects of Exenatide Combined with Lifestyle Modification in Patients with Type 2 Diabetes

Apovian, C. M., Bergenstal, R. M., Cuddihy, R. M., Qu, Y., Lenox, S., Lewis, M. S., & Glass, L. C. (2010) · The American Journal of Medicine · doi:10.1016/j.amjmed.2009.11.019 · Cited by 127 · see citing works

Exenatide elicits sustained glycaemic control and progressive reduction of body weight in patients with type 2 diabetes inadequately controlled by sulphonylureas with or without metformin

Riddle, M. C., Henry, R. R., Poon, T., Bei, Z., Mac, S. M., Holcombe, J. H., Kim, D. D. H., & Maggs, D. G. (2006) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.646 · Cited by 126 · see citing works

Exenatide Versus Glibenclamide in Patients with Diabetes

Derosa, G., Maffioli, P., Salvadeo, S. A. T., Ferrari, I., Ragonesi, P. D., Querci, F., Franzetti, I. G., Gadaleta, G., Ciccarelli, L., Piccinni, M. N., et al. (2010) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2009.0141 · Cited by 125 · see citing works

DURATION‐2: efficacy and safety of switching from maximum daily sitagliptin or pioglitazone to once‐weekly exenatide

Wysham, C., Bergenstal, R. M., Malloy, J. L., Yan, P., Walsh, B., Malone, J. K., & Taylor, K. (2011) · Diabetic Medicine · doi:10.1111/j.1464-5491.2011.03301.x · Cited by 118 · see citing works

GLP-1 receptor stimulation depresses heart rate variability and inhibits neurotransmission to cardiac vagal neurons

Griffioen, K. J. S., Wan, R., Okun, E., Wang, X., Lovett-Barr, M. R., Li, Y., Mughal, M. R., Mendelowitz, D., & Mattson, M. P. (2010) · Cardiovascular Research · doi:10.1093/cvr/cvq271 · Cited by 110 · see citing works

A Meta-Analysis of Placebo-Controlled Clinical Trials Assessing the Efficacy and Safety of Incretin-Based Medications in Patients with Type 2 Diabetes

Fakhoury, W. K. H., LeReun, C., & Wright, D. (2010) · Pharmacology · doi:10.1159/000314690 · Cited by 110 · see citing works

Effects of Exenatide Plus Rosiglitazone on β-Cell Function and Insulin Sensitivity in Subjects With Type 2 Diabetes on Metformin

DeFronzo, R. A., Triplitt, C., Qu, Y., Lewis, M. S., Maggs, D., & Glass, L. C. (2010) · Diabetes Care · doi:10.2337/dc09-1521 · Cited by 104 · see citing works

Effects of glucagon-like peptide-1, yohimbine, and nitrergic modulation on sympathetic and parasympathetic activity in humans

Bharucha, A. E., Charkoudian, N., Andrews, C. N., Camilleri, M., Sletten, D., Zinsmeister, A. R., & Low, P. A. (2008) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00153.2008 · Cited by 98 · cited 1× · see citing works

Liraglutide provides similar glycaemic control as glimepiride (both in combination with metformin) and reduces body weight and systolic blood pressure in Asian population with type 2 diabetes from China, South Korea and India: a 16‐week, randomized, double‐blind, active control trial *

Yang, W., Chen, L., Ji, Q., Liu, X., Ma, J., Tandon, N., Bhattacharyya, A., Kumar, A., Kim, K.-W., Yoon, K., et al. (2010) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01323.x · Cited by 91 · see citing works

Exenatide Twice Daily Versus Premixed Insulin Aspart 70/30 in Metformin-Treated Patients With Type 2 Diabetes

Gallwitz, B., Böhmer, M., Segiet, T., Mölle, A., Milek, K., Becker, B., Helsberg, K., Petto, H., Peters, N., & Bachmann, O. P. (2011) · Diabetes Care · doi:10.2337/dc10-1900 · Cited by 88 · see citing works

Efficacy and safety of exenatide in patients of Asian descent with type 2 diabetes inadequately controlled with metformin or metformin and a sulphonylurea

Gao, Y., Yoon, K., Chuang, L., Mohan, V., Ning, G., Shah, S., Jang, H. C., Wu, T.-J., Johns, D., Northrup, J., et al. (2008) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2008.09.037 · Cited by 87 · see citing works

Association of Average Heart Rate on 24-Hour Ambulatory Electrocardiograms With Incidence of New Coronary Events at 48-Month Follow-Up in 1,311 Patients (Mean Age 81 Years) With Heart Disease and Sinus Rhythm

Aronow, W. S., Ahn, C. W., Mercando, A. D., & Epstein, S. (1996) · The American Journal of Cardiology · doi:10.1016/s0002-9149(96)90077-6 · Cited by 83 · see citing works

Efficacy and safety of biphasic insulin aspart 70/30 versus exenatide in subjects with type 2 diabetes failing to achieve glycemic control with metformin and a sulfonylurea

Bergenstal, R. M., Lewin, A. J., Bailey, T. S., Chang, D., Gylvin, T., Roberts, V. L., & for the NovoLog Mix-vs.-Exenatide Study Group (2008) · Current Medical Research and Opinion · doi:10.1185/03007990802597951 · Cited by 82 · see citing works

An overview of the pharmacokinetics, efficacy and safety of liraglutide

Bode, B. W. (2012) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2011.12.015 · Cited by 80 · see citing works

Patient‐reported outcomes following treatment with the human GLP‐1 analogue liraglutide or glimepiride in monotherapy: results from a randomized controlled trial in patients with type 2 diabetes

Bode, B. W., Testa, M. A., MAGWIRE, M. L., Hale, P. M., Hammer, M., Blonde, L., Garber, A. J., & on behalf of the LEAD‐3 Study Group (2010) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01196.x · Cited by 76 · see citing works

A placebo‐controlled trial of exenatide twice‐daily added to thiazolidinediones alone or in combination with metformin

Liutkus, J., Guzmán, J. R., Norwood, P. C., Pop, L., Northrup, J., Cao, D., & TRAUTMANN, M. E. (2010) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01251.x · Cited by 74 · see citing works

Exenatide or glimepiride added to metformin on metabolic control and on insulin resistance in type 2 diabetic patients

Derosa, G., Putignano, P., Bossi, A. C., Bonaventura, A., Querci, F., Franzetti, I., Guazzini, B., Testori, G., Fogari, E., & Maffioli, P. (2011) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2011.05.051 · Cited by 68 · see citing works

Liraglutide improves treatment satisfaction in people with Type 2 diabetes compared with sitagliptin, each as an add on to metformin

Davies, M. J., Pratley, R. E., Hammer, M., Thomsen, A. B., & Cuddihy, R. M. (2010) · Diabetic Medicine · doi:10.1111/j.1464-5491.2010.03074.x · Cited by 60 · see citing works

Resting heart rate in patients with stable coronary artery disease and diabetes: a report from the Euro Heart Survey on Diabetes and the Heart

Anselmino, M., Öhrvik, J., Rydén, L., & on behalf of the Euro Heart Survey Investigators (2010) · European Heart Journal · doi:10.1093/eurheartj/ehq368 · Cited by 52 · see citing works

Exenatide Exhibits Dose-Dependent Effects on Glycemic Control over 12 Weeks in Japanese Patients with Suboptimally Controlled Type 2 Diabetes

Kadowaki, T., Namba, M., Yamamura, A., Sowa, H., Wolka, A. M., & Brodows, R. G. (2009) · Endocrine Journal · doi:10.1507/endocrj.k08e-296 · Cited by 52 · see citing works

Durability of Effects of Exenatide Treatment on Glycemic Control, Body Weight, Systolic Blood Pressure, C-Reactive Protein, and Triglyceride Concentrations

Varanasi, A., Chaudhuri, A., Dhindsa, S., Arora, A., Lohano, T., Vora, M. R., & Dandona, P. (2010) · Endocrine Practice · doi:10.4158/ep10199.or · Cited by 35 · see citing works

The Association of British Clinical Diabetologists (ABCD) nationwide exenatide audit

Ryder, R. E. J., Thong, K. Y., CULL, M. L., Mills, A., Walton, C., & Winocour, P. H. (2010) · Practical Diabetes · doi:10.1002/pdi.1522 · Cited by 33 · see citing works

Autonomic nervous system‐dependent and ‐independent cardiovascular effects of exendin‐4 infusion in conscious rats

Gardiner, S. M., March, J. E., Kemp, P. A., & Bennett, T. M. (2008) · British Journal of Pharmacology · doi:10.1038/bjp.2008.75 · Cited by 28 · see citing works

Effects of a long‐acting GLP‐1 mimetic (PF‐04603629) on pulse rate and diastolic blood pressure in patients with type 2 diabetes mellitus

Gustavson, S. M., Chen, D., Somayaji, V. R., Hudson, K. J., Baltrukonis, D. J., Singh, J., Boyden, T. L., & Calle, R. A. (2011) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01479.x · Cited by 21 · see citing works

Effects of glucagon-like peptide-1 (7–36) amide on neurohypophysial hormone secretion induced by acute hyperosmotic challenge

Bojanowska, E., & Stempniak, B. (2003) · Neuropeptides · doi:10.1016/s0143-4179(03)00003-9 · Cited by 4 · see citing works

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes

Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629 · see citing works

A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management

Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724 · see citing works

Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial

Davies, M. J., Bergenstal, R., Bode, B., Kushner, R. F., Lewin, A., Skjøth, T. V., Andreasen, A. H., Jensen, C. B., DeFronzo, R. A., & for the NN8022-1922 Study Group (2015) · JAMA · doi:10.1001/jama.2015.9676 · Cited by 1,198 · see citing works

Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors

Nauck, M. A., Meier, J. J., Cavender, M. A., Abd El Aziz, M., & Drucker, D. J. (2017) · Circulation · doi:10.1161/circulationaha.117.028136 · Cited by 582 · see citing works

Untitled work

Filippatos, T. D., Panagiotopoulou, T. V., & Elisaf, M. S. (2014) · The Review of Diabetic Studies · Cited by 560 · see citing works

Efficacy and Safety of Dulaglutide Monotherapy Versus Metformin in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-3)

Umpierrez, G., Tofé Povedano, S., Pérez Manghi, F., Shurzinske, L., & Pechtner, V. (2014) · Diabetes Care · doi:10.2337/dc13-2759 · Cited by 341 · see citing works

Drugs Commonly Associated With Weight Change: A Systematic Review and Meta-analysis

Domecq, J. P., Prutsky, G. J., Leppin, A. L., Sonbol, M. B., Altayar, O., Undavalli, C., Wang, Z., Elraiyah, T. A., Brito, J. P., Mauck, K. F., et al. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-3421 · Cited by 334 · see citing works

Liraglutide for weight management: a critical review of the evidence

Mehta, A., Marso, S. P., & Neeland, I. J. (2017) · Obesity Science & Practice · doi:10.1002/osp4.84 · Cited by 311 · see citing works

Review of head‐to‐head comparisons of glucagon‐like peptide‐1 receptor agonists

Madsbad, S. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12596 · Cited by 305 · see citing works

Impact of GLP-1 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: A systematic review and network meta-analysis

Sun, F., Wu, S., Guo, S., Yu, K., Yang, Z., Li, L., Zhang, Y., Quan, X., Ji, L., & Zhan, S. (2015) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2015.07.015 · Cited by 304 · see citing works

Pleiotropic Effects of GLP-1 and Analogs on Cell Signaling, Metabolism, and Function

Rowlands, J., Heng, J., Newsholme, P., & Carlessi, R. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00672 · Cited by 302 · see citing works

Contrasting Effects of Lixisenatide and Liraglutide on Postprandial Glycemic Control, Gastric Emptying, and Safety Parameters in Patients With Type 2 Diabetes on Optimized Insulin Glargine With or Without Metformin: A Randomized, Open-Label Trial

Meier, J. J., Rosenstock, J., Hincelin-Méry, A., Roy-Duval, C., Delfolie, A., Coester, H.-V., Menge, B. A., Forst, T., & Kapitza, C. (2015) · Diabetes Care · doi:10.2337/dc14-1984 · Cited by 262 · see citing works

Fresh insights into glucocorticoid-induced diabetes mellitus and new therapeutic directions

Li, J.-X., & Cummins, C. L. (2022) · Nature Reviews Endocrinology · doi:10.1038/s41574-022-00683-6 · Cited by 273 · see citing works

Effects of Glucagon‐Like Peptide‐1 Receptor Agonists, Sodium‐Glucose Cotransporter‐2 Inhibitors, and Their Combination on Endothelial Glycocalyx, Arterial Function, and Myocardial Work Index in Patients With Type 2 Diabetes Mellitus After 12‐Month Treatment

Ikonomidis, I., Pavlidis, G., Thymis, J., Birba, D., Kalogeris, A., Kousathana, F., Kountouri, A., Balampanis, K., Parissis, J., Andreadou, I., et al. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.119.015716 · Cited by 199 · see citing works

Pharmacotherapy of type 2 diabetes: An update

Upadhyay, J., Pοlyzos, S. A., Perakakis, N., Thakkar, B., Paschou, S. Α., Katsiki, N., UNDERWOOD, P. C., Park, K., Seufert, J., Kang, E. S., et al. (2017) · Metabolism · doi:10.1016/j.metabol.2017.08.010 · Cited by 190 · see citing works

The gut–renal axis: do incretin-based agents confer renoprotection in diabetes?

Muskiet, M. H. A., Smits, M. M., Morsink, L. M., & Diamant, M. (2013) · Nature Reviews Nephrology · doi:10.1038/nrneph.2013.272 · Cited by 182 · see citing works

Extraglycemic Effects of SGLT2 Inhibitors: A Review of the Evidence

Bonora, B. M., Avogaro, A., & Fadini, G. P. (2020) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s233538 · Cited by 177 · see citing works

Effects of glucagon‐like peptide‐1 receptor agonists on cardiovascular risk: a meta‐analysis of randomized clinical trials

Monami, M., Dicembrini, I., Nardini, C., Fiordelli, I., & Mannucci, E. (2013) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12175 · Cited by 174 · see citing works

Evolution of pharmacological obesity treatments: focus on adverse side‐effect profiles

Krentz, A. J., Fujioka, K., & Hompesch, M. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12657 · Cited by 168 · see citing works

Differential effects of glucagon-like peptide-1 receptor agonists on heart rate

Lorenz, M., Lawson, F., Owens, D., Raccah, D., Roy-Duval, C., Lehmann, A., Perfetti, R., & Blonde, L. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0490-6 · Cited by 166 · see citing works

A novel dual glucagon‐like peptide and glucagon receptor agonist SAR425899: Results of randomized, placebo‐controlled first‐in‐human and first‐in‐patient trials

Tillner, J., Posch, M. G., Wagner, F., Teichert, L., Hijazi, Y., Einig, C., Keil, S., Haack, T., Wagner, M., Bossart, M., et al. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13494 · Cited by 164 · see citing works

Efficacy and safety of dulaglutide in the treatment of type 2 diabetes: a comprehensive review of the dulaglutide clinical data focusing on the AWARD phase 3 clinical trial program

Jendle, J., Grunberger, G., Blevins, T., Giorgino, F., Hietpas, R. T., & Botros, F. T. (2016) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2810 · Cited by 158 · see citing works

A review of GLP‐1 receptor agonists in type 2 diabetes: A focus on the mechanism of action of once‐weekly agents

Cornell, S. (2020) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.13230 · Cited by 156 · see citing works

A meta‐analysis comparing clinical effects of short‐ or long‐acting <scp>GLP</scp> ‐1 receptor agonists versus insulin treatment from head‐to‐head studies in type 2 diabetic patients

Abd El Aziz, M. S., Kahle, M., Meier, J. J., & Nauck, M. A. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12804 · Cited by 155 · see citing works

Semaglutide for type 2 diabetes mellitus: A systematic review and meta‐analysis

Andreadis, P., Karagiannis, T., Malandris, K., Avgerinos, I., Liakos, A., Manolopoulos, A., Bekiari, E., Matthews, D. R., & Τσάπας, Α. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13361 · Cited by 154 · see citing works

Safety and efficacy of once‐weekly dulaglutide versus sitagliptin after 2 years in metformin‐treated patients with type 2 diabetes ( AWARD ‐5): a randomized, phase III study

Weinstock, R. S., Guerci, B., Umpierrez, G. E., Nauck, M. A., Skrivanek, Z., & Miličević, Z. (2015) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12479 · Cited by 151 · see citing works

Glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes: Differences and similarities

Lund, A., Knop, F. K., & Vilsbøll, T. (2014) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2014.03.005 · Cited by 148 · see citing works

Effects of 6-month treatment with the glucagon like peptide-1 analogue liraglutide on arterial stiffness, left ventricular myocardial deformation and oxidative stress in subjects with newly diagnosed type 2 diabetes

Lambadiari, V., Pavlidis, G., Kousathana, F., Varoudi, M., Vlastos, D., Maratou, E., Georgiou, D., Andreadou, I., Parissis, J., Triantafyllidi, H., et al. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0646-z · Cited by 146 · see citing works

Effects of the Once-Weekly Glucagon-Like Peptide-1 Receptor Agonist Dulaglutide on Ambulatory Blood Pressure and Heart Rate in Patients With Type 2 Diabetes Mellitus

Ferdinand, K. C., White, W. B., Calhoun, D. A., Lonn, E., Sager, P. T., Brunelle, R. L., Jiang, H. H., Threlkeld, R. J., Robertson, K. E., & Geiger, M. J. (2014) · Hypertension · doi:10.1161/hypertensionaha.114.03062 · Cited by 146 · see citing works

Cardiovascular effects of Glucagon-like peptide 1 (GLP-1) receptor agonists

Saraiva, F. K., & Sposito, A. C. (2014) · Cardiovascular Diabetology · doi:10.1186/s12933-014-0142-7 · Cited by 143 · see citing works

GLP-1 Receptor Agonists and Cardiovascular Disease in Patients with Type 2 Diabetes

Olmo-García, M. I. D., & Merino-Torres, J. F. (2018) · Journal of Diabetes Research · doi:10.1155/2018/4020492 · Cited by 144 · see citing works

Liraglutide in an Adolescent Population with Obesity: A Randomized, Double-Blind, Placebo-Controlled 5-Week Trial to Assess Safety, Tolerability, and Pharmacokinetics of Liraglutide in Adolescents Aged 12-17 Years

Danne, T., Biester, T., Kapitzke, K., Jacobsen, S. H., Jacobsen, L. V., Petri, K. C. C., Hale, P. M., & Kordonouri, O. (2016) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2016.10.076 · Cited by 135 · see citing works

Tirzepatide for the treatment of adults with type 2 diabetes: An endocrine perspective

De Block, C., Bailey, C., Wysham, C., Hemmingway, A., Allen, S. E., & Peleshok, J. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14831 · Cited by 121 · see citing works

Should the sympathetic nervous system be a target to improve cardiometabolic risk in obesity?

Lambert, É., Straznicky, N. E., Dixon, J. B., & Lambert, G. W. (2015) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00096.2015 · Cited by 115 · see citing works

A genomic approach to therapeutic target validation identifies a glucose-lowering GLP1R variant protective for coronary heart disease

Scott, R. A., Freitag, D. F., Li, L., Chu, A. Y., Surendran, P., Young, R., Grarup, N., Stančáková, A., Chen, Y., Varga, T. V., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad3744 · Cited by 115 · see citing works

Reduction of visceral fat by liraglutide is associated with ameliorations of hepatic steatosis, albuminuria, and micro-inflammation in type 2 diabetic patients with insulin treatment: a randomized control trial

Bouchi, R., Nakano, Y., Fukuda, T., Takeuchi, T., Murakami, M., Minami, I., Izumiyama, H., Hashimoto, K., Yoshimoto, T., & Ogawa, Y. (2017) · Endocrine Journal · doi:10.1507/endocrj.ej16-0449 · Cited by 113 · see citing works

<scp>GLP</scp> ‐1 receptor agonists: Nonglycemic clinical effects in weight loss and beyond

Ryan, D., & Acosta, A. (2015) · Obesity · doi:10.1002/oby.21107 · Cited by 112 · see citing works

Adding liraglutide to lifestyle changes, metformin and testosterone therapy boosts erectile function in diabetic obese men with overt hypogonadism

Giagulli, V. A., Carbone, M. D., Ramunni, M. I., Licchelli, B., De Pergola, G., Sabbà, C., Guastamacchia, E., & Triggiani, V. (2015) · Andrology · doi:10.1111/andr.12099 · Cited by 109 · see citing works

Dapagliflozin once‐daily and exenatide once‐weekly dual therapy: A 24‐week randomized, placebo‐controlled, phase <scp>II</scp> study examining effects on body weight and prediabetes in obese adults without diabetes

Lundkvist, P., Sjöström, C. D., Amini, S., Pereira, M. J., Johnsson, E., & Eriksson, J. W. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12779 · Cited by 108 · see citing works

Rationale and design of the EXenatide Study of Cardiovascular Event Lowering (EXSCEL) trial

Holman, R. R., Bethel, M. A., George, J. T., Sourij, H., Doran, Z., Keenan, J. F., Khurmi, N. S., Mentz, R. J., Oulhaj, A., Buse, J. B., et al. (2015) · American Heart Journal · doi:10.1016/j.ahj.2015.12.009 · Cited by 105 · see citing works

Effects of Glucagon-Like Peptide-1 Receptor Agonists on Weight Loss in Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis

Sun, F., Chai, S., Li, L., Yu, K., Yang, Z., Wu, S., Zhang, Y., JI, L., & Zhan, S. (2015) · Journal of Diabetes Research · doi:10.1155/2015/157201 · Cited by 104 · see citing works

Control of Food Intake by Gastrointestinal Peptides: Mechanisms of Action and Possible Modulation in the Treatment of Obesity

Prinz, P., & Stengel, A. (2017) · Journal of Neurogastroenterology and Motility · doi:10.5056/jnm16194 · Cited by 103 · see citing works

Glucagon-like peptide-1 (GLP-1) receptor agonists and their cardiovascular benefits—the role of the GLP-1 receptor

Helmstädter, J., Keppeler, K., Küster, L., Münzel, T., Daiber, A., & Steven, S. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15462 · Cited by 99 · see citing works

Links between Metabolic Syndrome and Hypertension: The Relationship with the Current Antidiabetic Drugs

Stanciu, S. M., Rusu, E., Miricescu, D., Radu, A. C., Axinia, B., Vrabie, A.-M., Ionescu, R. F., Jinga, M., & Sîrbu, C. A. (2023) · Metabolites · doi:10.3390/metabo13010087 · Cited by 113 · see citing works

Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: Insights from a patient-level pooled analysis of six randomized clinical trials

Fonseca, V. A., DeVries, J. H., Henry, R. R., Donsmark, M., Thomsen, H. F., & Plutzky, J. (2014) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2014.01.009 · Cited by 98 · see citing works

Harnessing glucagon‐like peptide‐1 receptor agonists for the pharmacological treatment of overweight and obesity

Burcelin, R., & Gourdy, P. (2016) · Obesity Reviews · doi:10.1111/obr.12465 · Cited by 97 · see citing works

Once‐weekly glucagon‐like peptide‐1 receptor agonist dulaglutide is non‐inferior to once‐daily liraglutide and superior to placebo in J apanese patients with type 2 diabetes: a 26‐week randomized phase III study

Miyagawa, J., Odawara, M., Takamura, T., Iwamoto, N., Takita, Y., & Imaoka, T. (2015) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12534 · Cited by 98 · see citing works

Effects of Liraglutide on Heart Rate and Heart Rate Variability: A Randomized, Double-Blind, Placebo-Controlled Crossover Study

Kumarathurai, P., Anholm, C., Larsen, B. S., Olsen, R. H., Madsbad, S., Kristiansen, O., Nielsen, O. W., Haugaard, S. B., & Sajadieh, A. (2017) · Diabetes Care · doi:10.2337/dc16-1580 · Cited by 96 · see citing works

GLP-1 Agonists and Blood Pressure: A Review of the Evidence

Goud, A., Zhong, J., Peters, M. C., Brook, R. D., & Rajagopalan, S. (2016) · Current Hypertension Reports · doi:10.1007/s11906-015-0621-6 · Cited by 93 · see citing works

Effects of liraglutide on left ventricular function in patients with non-ST-segment elevation myocardial infarction

Chen, W.-R., Shen, X., Zhang, Y., Chen, Y., Hu, S.-Y., Qian, G., Wang, J., Yang, J., Wang, Z., & Tian, F. (2015) · Endocrine · doi:10.1007/s12020-015-0798-0 · Cited by 88 · see citing works

Gut microbiota, hypertension and chronic kidney disease: Recent advances

Sircana, A., Michieli, F. D., Parente, R., Framarin, L., Leone, N., Berrutti, M., Paschetta, E., Bongiovanni, D., & Musso, G. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.01.013 · Cited by 86 · see citing works

Liraglutide in people treated for type 2 diabetes with multiple daily insulin injections: Randomised clinical trial (MDI Liraglutide trial)

Lind, M., Hirsch, I. B., Tuomilehto, J., Dahlqvist, S., Ahrén, B., Torffvit, O., Attvall, S., Ekelund, M., Filipsson, K., Tengmark, B.-O., et al. (2015) · BMJ · doi:10.1136/bmj.h5364 · Cited by 82 · see citing works

Mechanistic insights regarding the role of SGLT2 inhibitors and GLP1 agonist drugs on cardiovascular disease in diabetes

Garg, V., Verma, S., & Connelly, K. (2019) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2019.07.005 · Cited by 82 · see citing works

Liraglutide prevents and reverses monocrotaline-induced pulmonary arterial hypertension by suppressing ET-1 and enhancing eNOS/sGC/PKG pathways

Lee, M., Tsai, K., Hsu, J., Shin, S., Wu, J., & Yeh, J. (2016) · Scientific Reports · doi:10.1038/srep31788 · Cited by 81 · see citing works

Canagliflozin, dapagliflozin and empagliflozin monotherapy for treating type 2 diabetes: systematic review and economic evaluation

Johnston, R., Uthman, O. A., Cummins, E., Clar, C., Royle, P., Colquitt, J. L., Tan, B. K., Clegg, A. J., Shantikumar, S., Court, R. A., et al. (2017) · Health Technology Assessment · doi:10.3310/hta21020 · Cited by 81 · see citing works

Efficacy of liraglutide in treating type 2 diabetes mellitus complicated with non-alcoholic fatty liver disease

Tian, F., Zheng, Z., Zhang, D., He, S., & Shen, J. (2018) · Bioscience Reports · doi:10.1042/bsr20181304 · Cited by 80 · see citing works

Diabetes Mellitus Secondary to Cushing’s Disease

Barbot, M., Ceccato, F., & Scaroni, C. M. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00284 · Cited by 78 · see citing works

Pharmacodynamics, pharmacokinetics and safety of multiple ascending doses of the novel dual glucose‐dependent insulinotropic polypeptide/glucagon‐like peptide‐1 agonist <scp>RG</scp> 7697 in people with type 2 diabetes mellitus

Schmitt, C., Portron, A., Jadidi, S., Sarkar, N., & DiMarchi, R. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13024 · Cited by 74 · see citing works

Time course and mechanisms of the anti‐hypertensive and renal effects of liraglutide treatment

von Scholten, B. J., Lajer, M., Goetze, J. P., Persson, F., & Rossing, P. (2015) · Diabetic Medicine · doi:10.1111/dme.12594 · Cited by 73 · see citing works

Effect of glutamine supplementation on cardiovascular risk factors in patients with type 2 diabetes

Mansour, A., Tehrani, M. R. M., Qorbani, M., Heshmat, R., Larijani, B. A., & Hosseini, S. (2014) · Nutrition · doi:10.1016/j.nut.2014.05.014 · Cited by 70 · see citing works

Near‐normalization of glycaemic control with glucagon‐like peptide‐1 receptor agonist treatment combined with exercise in patients with type 2 diabetes

Mensberg, P., Nyby, S., Jørgensen, P. G., Storgaard, H., Jensen, M. T., Sivertsen, J., Holst, J. J., Kiens, B., Richter, E. A., Knop, F. K., et al. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12797 · Cited by 73 · see citing works

Stimulation of GLP-1 Secretion Downstream of the Ligand-Gated Ion Channel TRPA1

Emery, E. C., Diakogiannaki, E., Gentry, C., Psichas, A., Habib, A. M., Bevan, S., Fischer, M. J. M., Reimann, F. M., & Gribble, F. M. (2014) · Diabetes · doi:10.2337/db14-0737 · Cited by 67 · see citing works

Glucagon-like peptide-1: effect on pro-atrial natriuretic peptide in healthy males

Skov, J., Holst, J. J., Gøtze, J. P., Frøkiær, J., & Christiansen, J. S. (2013) · Endocrine Connections · doi:10.1530/ec-13-0087 · Cited by 65 · see citing works

Potential side effects to GLP-1 agonists: understanding their safety and tolerability

Consoli, A., & Formoso, G. (2014) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2015.987122 · Cited by 63 · see citing works

The physiological role of the brain GLP-1 system in stress

Holt, M. K., & Trapp, S. (2016) · Cogent Biology · doi:10.1080/23312025.2016.1229086 · Cited by 63 · see citing works

Exenatide acutely increases heart rate in parallel with augmented sympathetic nervous system activation in healthy overweight males

Smits, M. M., Muskiet, M. H. A., Tonneijck, L., Hoekstra, T., Kramer, M. H. H., Diamant, M., & van Raalte, D. H. (2016) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12843 · Cited by 60 · see citing works

Obesity-Associated Organ Damage and Sympathetic Nervous Activity

Lambert, É., Esler, M., Schlaich, M. P., Dixon, J. B., Eikelis, N., & Lambert, G. W. (2019) · Hypertension · doi:10.1161/hypertensionaha.118.11676 · Cited by 60 · see citing works

Consensus Recommendations on GLP-1 RA Use in the Management of Type 2 Diabetes Mellitus: South Asian Task Force

Kalra, S., Das, A. K., Sahay, R. K., Baruah, M. P., TIWASKAR, M. H., Das, S., Chatterjee, S., Saboo, B., Bantwal, G., Bhattacharya, S., et al. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-0669-4 · Cited by 58 · see citing works

Side Effects Associated with Liraglutide Treatment for Obesity as Well as Diabetes

Seo, Y. (2020) · Journal of Obesity & Metabolic Syndrome · doi:10.7570/jomes20059 · Cited by 57 · see citing works

Glucagon‐like peptide‐1 receptor agonists modestly reduced blood pressure among patients with and without diabetes mellitus: A meta‐analysis and meta‐regression

Rivera, F. B., Lumbang, G. N. O., Gaid, D. R. M., Cruz, L. L. A., Magalong, J. V., Bantayan, N. R. B., Lara-Breitinger, K. M., Gulati, M., & Bakris, G. L. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15529 · Cited by 59 · see citing works

One-year treatment with liraglutide improved renal function in patients with type 2 diabetes: a pilot prospective study

Zavattaro, M., Caputo, M., Samà, M. T., Mele, C., Chasseur, L., Marzullo, P., Pagano, L., Mauri, M. G., Ponziani, M. C., Aimaretti, G., et al. (2015) · Endocrine · doi:10.1007/s12020-014-0519-0 · Cited by 57 · see citing works

Effects of glucagon-like peptide 1 receptor agonists on comorbidities in older patients with diabetes mellitus

Onoviran, O. F., Li, D., Smith, S. T., & Raji, M. A. (2019) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622319862691 · Cited by 59 · see citing works

Exenatide once-weekly improves metabolic parameters, endothelial dysfunction and carotid intima-media thickness in patients with type-2 diabetes: An 8-month prospective study

Patti, A. M., Nikolić, D., Magán‐Fernández, A., Giglio, R. V., Castellino, G., Chianetta, R., Citarrella, R., Corrado, E., Provenzano, F., Provenzano, V., et al. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.02.006 · Cited by 56 · see citing works

Do Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Cause Heart Failure?

Clifton, P. M. (2014) · Clinical Therapeutics · doi:10.1016/j.clinthera.2014.10.009 · Cited by 55 · see citing works

Pathophysiological Links Between Diabetes and Blood Pressure

Libianto, R., Batu, D., MacIsaac, R. J., Cooper, M. E., & Ekinci, E. I. (2018) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2018.01.010 · Cited by 54 · see citing works

Cardiometabolic effects of a new class of antidiabetic agents

Desouza, C. V., Gupta, N., & Patel, A. (2015) · Clinical Therapeutics · doi:10.1016/j.clinthera.2015.02.016 · Cited by 54 · see citing works

Effects of the glucagon-like peptide-1 receptor agonist liraglutide on systolic function in patients with coronary artery disease and type 2 diabetes: a randomized double-blind placebo-controlled crossover study

Kumarathurai, P., Anholm, C., Nielsen, O. W., Kristiansen, O. P., Mølvig, J., Madsbad, S., Haugaard, S. B., & Sajadieh, A. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0425-2 · Cited by 54 · see citing works

Modern Management of Cardiometabolic Continuum: From Overweight/Obesity to Prediabetes/Type 2 Diabetes Mellitus. Recommendations from the Eastern and Southern Europe Diabetes and Obesity Expert Group

Janež, A., Muzurović, E. M., Bogdański, P., Czupryniak, L., Fábryová, Ľ., Fras, Z., Guja, C., Haluzı́k, M., Kempler, P., Lalic, N. M., et al. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01615-5 · Cited by 53 · see citing works

Cardiovascular Effects of Glucagon-Like Peptide-1 Receptor Agonists

Kang, Y. M., & Jung, C. H. (2016) · Endocrinology and Metabolism · doi:10.3803/enm.2016.31.2.258 · Cited by 51 · see citing works

Dulaglutide

Thompson, A. M., & Trujillo, J. M. (2015) · Annals of Pharmacotherapy · doi:10.1177/1060028014564180 · Cited by 50 · see citing works

Basal Insulin Intensification in Patients with Type 2 Diabetes: A Review

Meece, J. D. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0395-3 · Cited by 51 · see citing works

Effect of liraglutide on blood pressure: a meta-analysis of liraglutide randomized controlled trials

Zhao, X., Huang, K., Zheng, M., & Duan, J. (2019) · BMC Endocrine Disorders · doi:10.1186/s12902-018-0332-5 · Cited by 51 · see citing works

Beyond glycemia: Comparing tirzepatide to GLP-1 analogues

Andraos, J., Muhar, H. K., & Smith, S. R. (2023) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-023-09825-1 · Cited by 50 · see citing works

Cardiovascular Safety of Incretin-Based Therapies in Type 2 Diabetes: Systematic Review of Integrated Analyses and Randomized Controlled Trials

Mannucci, E., & Monami, M. (2016) · Advances in Therapy · doi:10.1007/s12325-016-0432-4 · Cited by 48 · see citing works

Positron emission tomography imaging of the glucagon-like peptide-1 receptor in healthy and streptozotocin-induced diabetic pigs

Nalin, L., Selvaraju, R. K., Velikyan, I., Berglund, M., Andréasson, S., Wikstrand, A., Rydén, A., Lubberink, M., KANDEEL, F. R., Nyman, G. C., et al. (2014) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-014-2745-3 · Cited by 48 · see citing works

Glucagon-like polypeptide agonists in type 2 diabetes mellitus: efficacy and tolerability, a balance

Tella, S. H., & Rendell, M. (2015) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018815580257 · Cited by 48 · see citing works

Modulation of Cardiac Ventricular Excitability by GLP-1 (Glucagon-Like Peptide-1)

Ang, R., Mastitskaya, S., Hosford, P. S., Васильевна, Б. М., Specterman, M. J., Aziz, Q. H., Li, Y. H., Orini, M., Taggart, P. I., Lambiase, P. D., et al. (2018) · Circulation Arrhythmia and Electrophysiology · doi:10.1161/circep.118.006740 · Cited by 47 · see citing works

Safety and tolerability of exenatide once weekly in patients with type 2 diabetes: an integrated analysis of 4,328 patients

Gurney, K., MacConell, L., Malloy, J. L., Zhou, M., & Kolterman, O. (2015) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s77290 · Cited by 45 · see citing works

Counter‐regulatory hormone responses to hypoglycaemia in people with type 1 diabetes after 4 weeks of treatment with liraglutide adjunct to insulin: a randomized, placebo‐controlled, double‐blind, crossover trial

Pieber, T. R., Deller, S., Korsatko, S., Jensen, L., Christiansen, E., Madsen, J. C., & Heller, S. R. (2015) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12473 · Cited by 44 · see citing works

An overview of new GLP-1 receptor agonists for type 2 diabetes

Tomlinson, B., Hu, M., Zhang, Y., Chan, P., & Liu, Z.-M. (2015) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2016.1123249 · Cited by 44 · see citing works

Liraglutide prevents metabolic side-effects and improves recognition and working memory during antipsychotic treatment in rats

Babic, I., Gorak, A., Engel, M., Sellers, D., Else, P. L., Osborne, A. L., Pai, N. B., Huang, X., Nealon, J. R., & Weston–Green, K. (2018) · Journal of Psychopharmacology · doi:10.1177/0269881118756061 · Cited by 44 · see citing works

Exenatide induces aortic vasodilation increasing hydrogen sulphide, carbon monoxide and nitric oxide production

Sélley, E., Kun, S., Szijártó, I. A., Laczy, B., Kovács, T., Fülöp, F., Wittmann, I., & Molnár, G. A. (2014) · Cardiovascular Diabetology · doi:10.1186/1475-2840-13-69 · Cited by 43 · see citing works

After the LEADER trial and SUSTAIN-6, how do we explain the cardiovascular benefits of some GLP-1 receptor agonists?

Vergès, B. L., & Charbonnel, B. H. (2017) · Diabetes & Metabolism · doi:10.1016/s1262-3636(17)30067-8 · Cited by 42 · see citing works

Metabolic responses and benefits of glucagon‐like peptide‐1 (GLP‐1) receptor ligands

Tanday, N., Flatt, P. R., & Irwin, N. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15485 · Cited by 42 · see citing works

Clinical Pharmacology of Albiglutide, a GLP-1 Receptor Agonist

Young, M. A., Wald, J. A., Matthews, J. E., Scott, R., Hodge, R. J., Zhi, H., & Reinhardt, R. R. (2014) · Postgraduate Medicine · doi:10.3810/pgm.2014.11.2836 · Cited by 41 · see citing works

Comparison of Efficacy and Safety of Liraglutide 3.0 mg in Individuals with BMI above and below 35 kg/m²: A Post-hoc Analysis

le Roux, C. W., Aroda, V. R., Uddén, J., Cancino, A., Christensen, R. H. B., & Pi-Sunyer, X. (2017) · Obesity Facts · doi:10.1159/000478099 · Cited by 41 · see citing works

Towards Consistent Data Representation in the IoT Healthcare Landscape

Reda, R., Piccinini, F., & Carbonaro, A. (2018) · International Conference on Digital Health · doi:10.1145/3194658.3194668 · Cited by 40 · see citing works

Blood Pressure-Lowering Effects of Incretin-Based Diabetes Therapies

Lovshin, J. A., & Zinman, B. (2014) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2014.05.001 · Cited by 40 · see citing works

Effects of the glucagon-like peptide-1 receptor agonist liraglutide on 24-h ambulatory blood pressure in patients with type 2 diabetes and stable coronary artery disease

Kumarathurai, P., Anholm, C., Fabricius‐Bjerre, A., Nielsen, O. W., Kristiansen, O. P., Madsbad, S., Haugaard, S. B., & Sajadieh, A. (2017) · Journal of Hypertension · doi:10.1097/hjh.0000000000001275 · Cited by 39 · see citing works

Treatment potential of the GLP-1 receptor agonists in type 2 diabetes mellitus: a review

Østergaard, L., Frandsen, C. S., & Madsbad, S. (2016) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2016.1121808 · Cited by 38 · see citing works

Correspondence to

Ta, H., Rees, K., Effects, E. A., See, L., Uk, C., & Holt, D. T. A. (2012)

Impact of Glp-1RA on Heart Rate, Blood Pressure and Hypertension Among Type 2 Diabetes: A Systematic Review and Network Meta-Analysis

Sun, F., Wu, S., Chai, S., Yang, Z., Yu, K., & Zhan, S. (2014) · Value in Health · doi:10.1016/j.jval.2014.08.010 · Cited by 4 · see citing works

Impact of GLP-1 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: A systematic review and network meta-analysis

Sun, F., Wu, S., Guo, S., Yu, K., Yang, Z., Li, L., Zhang, Y., Quan, X., Ji, L., & Zhan, S. (2015) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2015.07.015 · Cited by 304 · see citing works

For peer review only Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: Systematic review and meta- analysis

Robinson, L. (2012)

Blood pressure‐lowering effects of <scp>GLP</scp> ‐1 receptor agonists exenatide and liraglutide: a meta‐analysis of clinical trials

Wang, B., Zhong, J., Lin, H., Zhao, Z., Yan, Z., He, H., Ni, Y., Liu, D., & Zhu, Z. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12085 · Cited by 225 · see citing works